Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 178, Issue 11, Pages 2168-2185Publisher
WILEY
DOI: 10.1111/bph.14851
Keywords
-
Categories
Ask authors/readers for more resources
LDL cholesterol plays a key role in atherosclerosis progression, and statin therapy is recommended for reducing LDL-C levels and cardiovascular disease risk. For patients unable to achieve sufficient LDL-C reduction with statins or are statin-intolerant, PCSK9 inhibitors are an alternative treatment that significantly reduces LDL-C levels and cardiovascular risk.
LDL cholesterol (LDL-C) plays a central role in the progression of atherosclerosis. Statin therapy for lowering LDL-C reduces the risk of atherosclerotic cardiovascular disease and is the recommended first-line treatment for patients with high LDL-C levels. However, some patients are unable to achieve an adequate reduction in LDL-C with statins or are statin-intolerant; thus, PCSK9 inhibitors were developed to reduce LDL-C levels, instead of statin therapy. PCSK9 monoclonal antibodies dramatically reduce LDL-C levels and cardiovascular risk, and promising new PCSK9 inhibitors using different mechanisms are currently being developed. The absolute benefit of LDL-C reduction depends on the individual absolute risk and the achieved absolute reduction in LDL-C. Therefore, PCSK9 inhibitors may provide the greatest benefits from further LDL-C reduction for the highest risk patients. Here, we focus on PCSK9-targeted therapies and discuss the challenges of LDL-C reduction for prevention of atherosclerotic cardiovascular disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available